Title: Infliximab for the treatment of refractory scleritis
暂无分享,去创建一个
[1] B. Zimmermann,et al. Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents , 2008 .
[2] J. Lopes,et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. , 2008, Inflammatory bowel diseases.
[3] S. Bickston,et al. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.
[4] G. Valesini,et al. Biological and clinical effects of anti-TNFalpha treatment. , 2007, Autoimmunity reviews.
[5] A. Till,et al. Current State of Biologicals in the Management of Systemic Vasculitis , 2007, Annals of the New York Academy of Sciences.
[6] L. Sobrin,et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. , 2007, Archives of ophthalmology.
[7] P. Sfikakis,et al. TUMOR NECROSIS FACTOR ANTAGONISTS: Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation , 2007, Retina.
[8] P. Mease. Infliximab (Remicade) in the treatment of psoriatic arthritis , 2006, Therapeutics and clinical risk management.
[9] C. Foster,et al. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. , 2006, International ophthalmology clinics.
[10] Justine R. Smith,et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. , 2005, Archives of ophthalmology.
[11] H. Lamb,et al. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. , 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[12] M. Raizman,et al. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. , 1994, American journal of ophthalmology.
[13] C. Foster,et al. An analysis of therapeutic decision for scleritis. , 1993, Ophthalmology.
[14] P. G. Watson,et al. Scleritis and episcleritis. , 1976, The British journal of ophthalmology.